Phaseline

Companies › Intralytix

Intralytix: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Immunology, Infectious disease.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EcoActive
Bacteriophage preparation targeting adherent-invasive E. coli (AIEC)
–Phase 1Crohn Disease–
ShigActive
Lytic bacteriophages targeting Shigella species
–Phase 1Shigellosis; Endocarditis, Bacterial–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05182749ShigActivePhase 1ShigellosisInfectious diseaseDec 2024
NCT03808103EcoActivePhase 1Crohn DiseaseImmunologyJun 2026
NCT06870409ShigActivePhase 3Endocarditis, BacterialInfectious diseaseFeb 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.